Whole-body PBPK model of cimetidine (OCT2/MATE and CYP3A4 DDI perpetrator drug)
This repository contains:
- a PK-Sim snapshot (*.json) file of the current PBPK model
- static content (e.g. text blocks, *.md files) as inputs for an evaluation plan
- an evaluation plan (evaluation-plan.json) to create an evaluation report using the snapshot and static text blocks to display the performance of the model
The latest release of the snapshot of the model, the evaluation plan and the static content can be found here.
The latest release of the PK-Sim project model file and the respective evaluation report can be found here.
This cimetidine model is intended to be used as perpetrator drug in OCT2/MATE- and CYP3A4-mediated drug-drug interactions (DDI).
The herein presented model was developed and published by Hanke et al. [1] and later on adjusted to account for structural changes coming with PK-Sim V10. It comprises transport by OCT1, MATE1 and OAT3 as well as glomerular filtration. It has been developed using 27 clinical studies of intravenous or oral administration, covering a broad dosing range of 100 to 800 mg.
Everyone interacting in the Open Systems Pharmacology community (codebases, issue trackers, chat rooms, mailing lists etc...) is expected to follow the Open Systems Pharmacology code of conduct.
We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the contribution guidelines. If you are contributing code, please be familiar with the coding standard.
The model code is distributed under the GPLv2 License.
[1] Hanke N, Türk D, Selzer D, Ishiguro N, Ebner T, Wiebe S, Müller F, Stopfer P, Nock V, Lehr T. A Comprehensive Whole‑Body Physiologically Based Pharmacokinetic Drug–Drug–Gene Interaction Model of Metformin and Cimetidine in Healthy Adults and Renally Impaired Individuals. Clinical Pharmacokinetics 2020, https://doi.org/10.1007/s40262-020-00896-w